At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
Cabozantinib S-malate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
In Brief
A Phase 1 clinical trial evaluating Cabozantinib S-malate, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Malignant Solid Neoplasm and 6 related conditions. Completed, enrolled 41 participants across 23 sites in 2 countries.
Detailed Summary
This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Thyroid Gland Medullary Carcinoma
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartNov 2012
Primary CompletionDec 2018
Study CompletionDec 2019
TodayJul 2026
First PostedOct 18, 2012
Enrollment StartNov 14, 2012
Primary CompletionDec 31, 2018
Study CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 13.7 years ago
Interventions
Cabozantinib S-malatedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies